Shares of Phreesia, Inc. (NYSE:PHR – Get Free Report) have received an average recommendation of “Hold” from the nineteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $16.6471.
Several equities analysts have recently issued reports on PHR shares. Wall Street Zen raised shares of Phreesia from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Truist Financial boosted their price objective on shares of Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a research note on Thursday, May 28th. DA Davidson restated a “buy” rating and issued a $14.00 price objective on shares of Phreesia in a report on Thursday, May 28th. Weiss Ratings raised Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. Finally, Barclays reaffirmed an “equal weight” rating and set a $10.00 target price (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th.
View Our Latest Stock Report on PHR
Hedge Funds Weigh In On Phreesia
Phreesia Stock Performance
NYSE:PHR opened at $12.28 on Friday. The stock has a market cap of $758.78 million, a P/E ratio of 81.84 and a beta of 0.85. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. The stock’s 50-day moving average is $10.52 and its 200-day moving average is $10.59. Phreesia has a 1-year low of $7.77 and a 1-year high of $32.76.
Phreesia (NYSE:PHR – Get Free Report) last released its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The company had revenue of $130.94 million during the quarter, compared to the consensus estimate of $130.08 million. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. The firm’s revenue was up 12.9% compared to the same quarter last year. Equities research analysts anticipate that Phreesia will post 0.39 earnings per share for the current year.
About Phreesia
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Featured Stories
- Five stocks we like better than Phreesia
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
